Precision Medicine in Oncology® | Specialty

The OncLive Precision Medicine in Oncology® condition center page is a comprehensive resource for clinical news and expert insights on precision-focused approaches in patients with cancer, with gene-targeted tyrosine kinase inhibitors and antibody-drug conjugates, checkpoint inhibitors, tumor-infiltrating lymphocyte therapy, and other tailored treatments. This page features news articles, interviews in written and video format, and podcasts that focus on updates and ongoing research with personalized therapies across solid and hematologic tumors.

I-O + PARP Inhibition for Triple-Negative Breast Cancer

March 29th 2019

Checkpoint Inhibitors for Triple-Negative Breast Cancer

March 29th 2019

Adjuvant T-DM1 Therapy in HER2+ Breast Cancer

March 29th 2019

Neoadjuvant Therapy in HER2+ Breast Cancer

March 29th 2019

Adjuvant Therapy for HR+ Breast Cancer

March 29th 2019

Genomic Testing & Adjuvant Therapy in HR+ Breast Cancer

March 29th 2019

CDK4/6 Inhibitors: Treating Beyond Progression

March 29th 2019

Selecting a CDK4/6 Inhibitor in HR+ Breast Cancer

March 29th 2019

Managing CDK4/6 Inhibitor Adverse Events

March 29th 2019

CDK4/6 Inhibitor Toxicity in HR+ Breast Cancer

March 29th 2019

CDK4/6 Inhibitors for HR+ Breast Cancer

March 29th 2019

Emerging Approaches for BRAF-Mutant Metastatic Melanoma

March 28th 2019

Treatment Sequencing in BRAF+ Metastatic Melanoma

March 28th 2019

Treatment Adherence and Response With BRAF-Targeted Therapy

March 28th 2019

BRAF/MEK Frontline Therapy in Metastatic Melanoma

March 28th 2019

Maximizing BRAF/MEK Inhibition in Melanoma

March 28th 2019

Recommendations for Managing BRAF+ Metastatic Melanoma

March 28th 2019

BRAF-Targeted Therapy in Melanoma: Toxicity Management

March 28th 2019

Treating Melanoma Patients With BRAF/MEK Dual-Targeted Therapy

March 28th 2019

The COLUMBUS Trial in BRAF-Mutant Melanoma

March 28th 2019